Učitavanje...
Targeting epigenetics as atherosclerosis treatment: an updated view
This review discusses the current developments on epigenetic inhibition as treatment for atherosclerosis. RECENT FINDINGS: The first phase III clinical trial targeting epigenetics in cardiovascular disease (CVD), BETonMACE, using the bromodomain inhibitor apabetalone (RVX-208) showed no significant...
Spremljeno u:
| Izdano u: | Curr Opin Lipidol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Lippincott Williams & Wilkins
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7752220/ https://ncbi.nlm.nih.gov/pubmed/33027226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOL.0000000000000711 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|